| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ORGO | Class A Common Stock | Sale | $900,000 | -200,000 | -34% | $4.50 | 386,297 | 15 Oct 2020 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $334,237 | -23,840 | -6.2% | $14.02 | 362,457 | 11 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $1,091,210 | -85,518 | -24% | $12.76 | 276,939 | 12 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $193,620 | -14,000 | -5.1% | $13.83 | 262,939 | 12 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $5,600 | -400 | -0.15% | $14.00 | 262,539 | 12 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $2,201,500 | -170,000 | -65% | $12.95 | 92,539 | 16 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $222,764 | -15,154 | -16% | $14.70 | 77,385 | 24 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $402,833 | -27,385 | -35% | $14.71 | 50,000 | 25 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $32,175 | -1,950 | -3.9% | $16.50 | 48,050 | 25 Feb 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $132,825 | -8,050 | -17% | $16.50 | 40,000 | 01 Mar 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $442,200 | -20,000 | -50% | $22.11* | 20,000 | 09 Apr 2021 | Direct |
Starr Wisdom, Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, and certain of their respective affiliates, including Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust, Alan Ades as Trustee of the Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016 and GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016, referred to collectively as the "Controlling Entities", are parties to a Controlling Stockholders' Agreement dated December 10, 2018 with Organogenesis Holdings Inc. (the "Stockholders' Agreement"). The Stockholders' Agreement, among other things, provides for nomination rights of the Controlling Entities with respect to four directors of the Issuer. As a result of the Stockholders' Agreement, the reporting person may be deemed to be a member of a group holding over 10% of the outstanding shares of common stock of the issuer for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. The reporting person disclaims beneficial ownership of the shares held by the other members of the Group and has no pecuniary interest in the shares held by the other members of the Group.